Clinical Trials Browser

Terminated × NIH × MK 2206 × Clear all

NCT01239342 2019-10-10

Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer

Phase 2 Terminated

43 enrolled 12 charts

Carcinoma, Renal Cell

NCT01776008 2018-05-08

Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer

Phase 2 Terminated

16 enrolled 5 charts

Breast Neoplasms

NCT01319539 2017-08-30

MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer

Phase 2 Terminated

12 enrolled 9 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01239355 2015-10-05

MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy

Phase 2 Terminated

15 enrolled 6 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT01281163 2015-08-27

Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer

Phase 1 Terminated

Breast Neoplasms

NCT01519427 2014-06-18

Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib

Phase 2 Terminated

2 enrolled 9 charts

Melanoma

NCT01705340 2013-09-30

Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery

Phase 1 Terminated

BreastGastrointestinal

Breast Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Breast Neoplasms, Male